Product Monograph: Vildagliptin & Vildagliptin + Metformin

Vildishal (Vildagliptin) and Vildishal M (Vildagliptin + Metformin) offer an advanced, well-tolerated approach to type 2 diabetes management by combining potent glycemic control with proven safety. As a selective DPP-4 inhibitor, Vildagliptin enhances incretin action to improve insulin secretion and reduce glucagon, while Metformin lowers hepatic glucose output and increases insulin sensitivity. Together, they address multiple pathophysiologic defects of diabetes, achieving significant HbA1c and fasting glucose reductions with low risk of hypoglycemia or weight gain. Supported by large clinical and real-world studies, including EDGE, VIRTUE, and G-FORCE, Vildishal ensures effective, weight-neutral, and patient-friendly therapy for both newly diagnosed and uncontrolled type 2 diabetes patients.